Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Barucker, Christian ^a   Bittner, Heiko J ^b   Chang, Philip K Y ^a   Cameron, Scott ^c,h   Hancock, Mark A ^a   Liebsch, Filip ^a   Hossain, Shireen ^a   Harmeier, Anja ^d,i   Shaw, Hunter ^c   Charron, François M ^a   Gensler, Manuel ^e   Dembny, Paul ^b,d   Zhuang, Wei ^e,j   Schmitz, Dietmar ^f   Rabe, Jürgen P ^e   Rao, Yong ^c   Lurz, Rudi ^g   Hildebrand, Peter W ^b   McKinney, R Anne ^a   Multhaup, Gerhard ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MCGILL UNIVERSITY   (Canada)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^g MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j Charite Universitätsmedizin Berlin Campus Mitte Department of Neurology ^*  (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); OLIGOPEPTIDE; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL; RAT; SYNAPSE; SYNAPTIC TRANSMISSION; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEIN AGGREGATION, PATHOLOGICAL; RATS; RATS, WISTAR; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84946145579     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15410     Document Type: Article

References (76)

1. Younkin, S. G. The role of A beta 42 in Alzheimers disease. J Physiol Paris 92, 289-92 (1998).
2. Gong, Y. et al. Alzheimers disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100, 10417-22 (2003).
3. Shankar, G. M. et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27, 2866-75 (2007).
4. Benilova, I., Karran, E. and De Strooper, B. The toxic Abeta oligomer and Alzheimers disease: an emperor in need of clothes. Nat Neurosci 15, 349-57 (2012).
5. Morley, J. E. et al. A physiological role for amyloid-beta protein:enhancement of learning and memory. J Alzheimers Dis 19, 441-9 (2010).
6. Puzzo, D. et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28, 14537-45 (2008).
7. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. and Lansbury, P. T., Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002).
8. Gouras, G. K. et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15-20 (2000).
9. LaFerla, F. M., Tinkle, B. T., Bieberich, C. J., Haudenschild, C. C. and Jay, G. The Alzheimers A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 9, 21-30 (1995).
10. Oddo, S., Caccamo, A., Smith, I. F., Green, K. N. and LaFerla, F. M. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol 168, 184-94 (2006).
11. Wirths, O. et al. Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol 12, 275-86 (2002).
12. Zhao, W. Q. et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246-60 (2008).
13. McLean, C. A. et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimers disease. Ann Neurol 46, 860-6 (1999).
14. Masliah, E. et al. Altered expression of synaptic proteins occurs early during progression of Alzheimers disease. Neurology 56, 127-9 (2001).
15. Walsh, D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-9 (2002).
16. Harmeier, A. et al. Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. J Neurosci 29, 7582-90 (2009).
17. Wei, W. et al. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci 13, 190-6 (2010).
18. Chang, P. K., Boridy, S., McKinney, R. A. and Maysinger, D. Letrozole Potentiates Mitochondrial and Dendritic Spine Impairments Induced by beta Amyloid. J Aging Res 2013, 538979 (2013).
19. Outeiro, T. F. et al. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun 351, 631-8 (2006).
20. Hirohata, M. et al. The anti-amyloidogenic effect is exerted against Alzheimers beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. Biochemistry 46, 1888-99 (2007).
21. Hudson, S. A., Ecroyd, H., Dehle, F. C., Musgrave, I. F. and Carver, J. A. (-)-epigallocatechin-3-gallate (EGCG) maintains kappacasein in its pre-fibrillar state without redirecting its aggregation pathway. J Mol Biol 392, 689-700 (2009).
22. LeVine, H., 3rd, Ding, Q., Walker, J. A., Voss, R. S. and Augelli-Szafran, C. E. Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly. Neurosci Lett 465, 99-103 (2009).
23. Hughes, E., Burke, R. M. and Doig, A. J. Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J Biol Chem 275, 25109-15 (2000).
24. Soto, C., Kindy, M. S., Baumann, M. and Frangione, B. Inhibition of Alzheimers amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 226, 672-80 (1996).
25. Hardy, J. and Selkoe, D. J. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science 297, 353-6 (2002).
26. Liu, W. et al. Structural role of glycine in amyloid fibrils formed from transmembrane alpha-helices. Biochemistry 44, 3591-7 (2005).
27. Sato, T. et al. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry 45, 5503-16 (2006).
28. Lashuel, H. A. et al. Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 332, 795-808 (2003).
29. Kirkwood, C. M. et al. Dendritic spine density, morphology, and fibrillar actin content surrounding amyloid-beta plaques in a mouse model of amyloid-beta deposition. J Neuropathol Exp Neurol 72, 791-800 (2013).
30. Matsuzaki, M. et al. Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat Neurosci 4, 1086-92 (2001).
31. Matsuzaki, M., Honkura, N., Ellis-Davies, G. C. and Kasai, H. Structural basis of long-term potentiation in single dendritic spines. Nature 429, 761-6 (2004).
32. Finelli, A., Kelkar, A., Song, H. J., Yang, H. and Konsolaki, M. A model for studying Alzheimers Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci 26, 365-75 (2004).
33. Basler, K. and Hafen, E. Sevenless and Drosophila eye development: a tyrosine kinase controls cell fate. Trends Genet 4, 74-9 (1988).
34. Pandey, U. B. and Nichols, C. D. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev 63, 411-36 (2011).
35. Elmquist, A. and Langel, U. In vitro uptake and stability study of pVEC and its all-D analog. Biol Chem 384, 387-93 (2003).
36. Youngblood, D. S., Hatlevig, S. A., Hassinger, J. N., Iversen, P. L. and Moulton, H. M. Stability of cell-penetrating peptidemorpholino oligomer conjugates in human serum and in cells. Bioconjug Chem 18, 50-60 (2007).
37. Belusic, G., Pirih, P. and Stavenga, D. G. Photoreceptor responses of fruitflies with normal and reduced arrestin content studied by simultaneous measurements of visual pigment fluorescence and ERG. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 196, 23-35 (2010).
38. Paulk, A., Millard, S. S. and van Swinderen, B. Vision in Drosophila: seeing the world through a models eyes. Annu Rev Entomol 58, 313-32 (2013).
39. Luhrs, T. et al. 3D structure of Alzheimers amyloid-beta(1-42) fibrils. Proc Natl Acad Sci USA 102, 17342-7 (2005).
40. Murakami, K. et al. Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimers disease at positions 21-23. Biochem Biophys Res Commun 294, 5-10 (2002).
41. Krone, M. G. et al. Effects of familial Alzheimers disease mutations on the folding nucleation of the amyloid beta-protein. J Mol Biol 381, 221-8 (2008).
42. Hayden, E. Y. and Teplow, D. B. Amyloid beta-protein oligomers and Alzheimers disease. Alzheimers Res Ther 5, 60 (2013).
43. Garber, K. Genentechs Alzheimers antibody trial to study disease prevention. Nat Biotechnol 30, 731-2 (2012).
44. van Groen, T. et al. Reduction of Alzheimers disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display. ChemMedChem 3, 1848-52 (2008).
45. Fraser, P. E. et al. Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues. J Mol Biol 244, 64-73 (1994).
46. Kirschner, D. A. et al. Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci USA 84, 6953-7 (1987).
47. Tjernberg, L. O. et al. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem 272, 12601-5 (1997).
48. Choi, S. H. et al. A three-dimensional human neural cell culture model of Alzheimers disease. Nature 515, 274-8 (2014).
49. Barucker, C. et al. Nuclear Translocation Uncovers the Amyloid Peptide Abeta42 as a Regulator of Gene Transcription. J Biol Chem 289, 20182-20191 (2014).
50. Barucker, C. et al. Alzheimer Amyloid Peptide Abeta42 Regulates Gene Expression of Transcription and Growth Factors. J Alzheimers Dis 44, 613-624 (2015).
51. Wu, J. W. et al. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. J Biol Chem 285, 6071-9 (2010).
52. De Roo, M., Klauser, P., Garcia, P. M., Poglia, L. and Muller, D. Spine dynamics and synapse remodeling during LTP and memory processes. Prog Brain Res 169, 199-207 (2008).
53. Hill, T. C. and Zito, K. LTP-induced long-term stabilization of individual nascent dendritic spines. J Neurosci 33, 678-86 (2013).
54. Engert, F. and Bonhoeffer, T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399, 66-70 (1999).
55. Maletic-Savatic, M., Malinow, R. and Svoboda, K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science 283, 1923-7 (1999).
56. Zhou, Q., Homma, K. J. and Poo, M. M. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 44, 749-57 (2004).
57. Stamatakou, E., Marzo, A., Gibb, A. and Salinas, P. C. Activity-dependent spine morphogenesis: a role for the actin-capping protein Eps8. J Neurosci 33, 2661-70 (2013).
58. Toni, N., Buchs, P. A., Nikonenko, I., Bron, C. R. and Muller, D. LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite. Nature 402, 421-5 (1999).
59. Matus, A. Actin-based plasticity in dendritic spines. Science 290, 754-8 (2000).
60. Hotulainen, P. and Hoogenraad, C. C. Actin in dendritic spines: connecting dynamics to function. J Cell Biol 189, 619-29 (2010).
61. Selkoe, D. J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192, 106-13 (2008).
62. Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. and Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-32 (2009).
63. Ashton-Beaucage, D. et al. A functional screen reveals an extensive layer of transcriptional and splicing control underlying RAS/ MAPK signaling in Drosophila. PLoS Biol 12, e1001809 (2014).
64. Stochmanski, S. J. et al. Expanded ATXN3 frameshifting events are toxic in Drosophila and mammalian neuron models. Hum Mol Genet 21, 2211-8 (2012).
65. Sievers, S. A. et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 475, 96-100 (2011).
66. Petrassi, H. M. et al. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J Am Chem Soc 127, 6662-71 (2005).
67. Bulawa, C. E. et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109, 9629-34 (2012).
68. Schweers, O., Schonbrunn-Hanebeck, E., Marx, A. and Mandelkow, E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem 269, 24290-7 (1994).
69. Steven, A. C. et al. Molecular substructure of a viral receptor-recognition protein. The gp17 tail-fiber of bacteriophage T7. J Mol Biol 200, 351-65 (1988).
70. Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. and Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27, 221-34 (2013).
71. Banks, J. L. et al. Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem 26, 1752-80 (2005).
72. Greenwood, J. R., Calkins, D., Sullivan, A. P. and Shelley, J. C. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J Comput Aided Mol Des 24, 591-604 (2010).
73. Tubert-Brohman, I., Sherman, W., Repasky, M. and Beuming, T. Improved docking of polypeptides with Glide. J Chem Inf Model 53, 1689-99 (2013).
74. De Paola, V., Arber, S. and Caroni, P. AMPA receptors regulate dynamic equilibrium of presynaptic terminals in mature hippocampal networks. Nat Neurosci 6, 491-500 (2003).
75. Gahwiler, B. H., Capogna, M., Debanne, D., McKinney, R. A. and Thompson, S. M. Organotypic slice cultures: a technique has come of age. Trends Neurosci 20, 471-7 (1997).
76. Chang, P. K., Prenosil, G. A., Verbich, D., Gill, R. and McKinney, R. A. Prolonged ampakine exposure prunes dendritic spines and increases presynaptic release probability for enhanced long-term potentiation in the hippocampus. Eur J Neurosci 40, 2766-76 (2014).